Expanding Hepatitis C Virus Treatment in the New Mexico State Prison System: Using the ECHO Model for Provider and Prison Peer Education.
New Mexico
hepatitis C
hepatitis C treatment
incarceration
prisons
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
13 Aug 2024
13 Aug 2024
Historique:
revised:
23
07
2024
received:
04
04
2024
accepted:
26
07
2024
medline:
13
8
2024
pubmed:
13
8
2024
entrez:
13
8
2024
Statut:
aheadofprint
Résumé
It is critical to address hepatitis C virus (HCV) in carceral settings to achieve worldwide elimination of the virus. We describe New Mexico's (NM) experience expanding HCV treatment in state prisons, supplemented with Project ECHO (ECHO; virtual mentorship through guided practice) and the NM Peer Education Program (NMPEP). We describe how using these programs may be a model for expanding treatment in prisons globally. ECHO, NM Corrections Department (NMCD) and Wexford Health Services (WHS) collaborate to treat HCV in state prisons and increase HCV knowledge among incarcerated persons using NMPEP. Each person arriving in prison is tested for HCV and those with active infection receive baseline labs, which are reviewed. Patients not meeting criteria for simplified treatment are presented to ECHO for expert guidance. Otherwise, patients are treated by WHS without consultation. NMPEP provides patient-to-patient education in prisons, addressing HCV myths and exploring treatment refusals. From December 2020 to June 2023, 3603 people had HCV viremia. In this study, 1685 people started treatment: 1280 were treated using the simplified algorithm and 405 were presented to ECHO. Of the 988 people who completed treatment and had sustained virologic response (SVR) labs drawn, 89.2% achieved SVR (i.e., cure). Most of the 107 people who did not achieve SVR had presumed reinfection. NMPEP trained 148 peer educators who educated 3832 peers about HCV prevention and treatment. HCV treatment in prisons can be expanded by implementing simplified treatment algorithms, use of the ECHO model for patients with advanced disease and peer education.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
A. C. Spaulding, S. S. Kennedy, J. Osei, et al., “Estimates of Hepatitis C Seroprevalence and Viremia in State Prison Populations in the United States,” Journal of Infectious Diseases 228, no. Suppl 3 (2023): S160–S167, https://doi.org/10.1093/infdis/jiad227.
Centers for Disease Control and Prevention, “Correctional Health Data and Statistics.” (2023), https://www.cdc.gov/correctionalhealth/health‐data.html.
N. Florko, “Hundreds of Incarcerated People Are Dying of Hep C‐ Even Though We Have a Simple Cure.” STAT (2022), https://www.statnews.com/2022/12/15/hundreds‐incarcerated‐people‐dying‐hepatitis‐c‐despite‐simple‐cure/#:~:text=The%20hepatitis%20C%2Drelated%20death%20rate%20in%20prisons%20in%202019,for%20age%20in%20either%20population.
Centers for Disease Control National Center for Health Statistics, “Chronic Liver Disease/Cirrhosis by State.” (2022), https://www.cdc.gov/nchs/pressroom/sosmap/liver_disease_mortality/liver_disease.htm.
J. D. Rich, S. A. Allen, and B. A. Williams, “Responding to Hepatitis C Through the Criminal Justice System,” New England Journal of Medicine 370, no. 20 (2014): 1871–1874, https://doi.org/10.1056/NEJMp1311941.
A. L. Beckman, A. Bilinski, R. Boyko, et al., “New Hepatitis C Drugs Are Very Costly and Unavailable to Many State Prisoners,” Health Affairs 35, no. 10 (2016): 1893–1901, https://doi.org/10.1377/hlhaff.2016.0296.
AASLD‐IDSA, “Recommendations for Testing, Managing, and Treating Hepatitis C.” (2022), http://www.hcvguidelines.org.
B. Hajarizadeh, J. Grebely, M. Byrne, et al., “Evaluation of Hepatitis C Treatment‐as‐Prevention Within Australian Prisons (SToP‐C): A Prospective Cohort Study,” Lancet Gastroenterology & Hepatology 6, no. 7 (2021): 533–546, https://doi.org/10.1016/S2468‐1253(21)00077‐7.
T. He, K. Li, M. S. Roberts, et al., “Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons,” Annals of Internal Medicine 164, no. 2 (2016): 84–92, https://doi.org/10.7326/M15‐0617.
M. J. Akiyama, N. Kronfli, J. Cabezas, et al., “Hepatitis C Elimination Among Incarcerated in Prisons: Challenges and Recommendations for Action Within a Health Systems Framework,” Lancet Gastroenterology & Hepatology 6, no. 5 (2021): 391–400, https://doi.org/10.1016/S2468‐1253(20)30365‐4.
S. Arora, K. Thornton, G. Murata, et al., “Outcomes of Treatment for Hepatitis C Virus Infection by Primary Careproviders,” New England Journal of Medicine 364 (2011): 2199–2207, https://doi.org/10.1056/NEJMoa1009370.
Civil Rights Litigation Clearinghouse, “White Paper: Policies for Expanding Hepatitis C Testing and Treatment in United States Prisons and Jails.” (2023), https://clearinghouse.net/special‐project/1/22.
M. Ghany, T. Morgan, and AASLD‐IDSA Hepatitis C Guidance Panel, “Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases‐Infectious Diseases Society of America Recommendations for Testing, Managing, and Treatment of Hepatitis C Virus Infection,” Hepatology 71, no. 2 (2020): 686–721, https://doi.org/10.1002/hep.31060.
L. I. Backus, P. S. Belperio, T. A. Shahoumian, T. A. Shahoumian, T. P. Loomis, and L. A. Mole, “Real‐World Effectiveness of Ledipasvir/Sofosbuvir in 4365 Treatment‐Naive, Genotype 1 Hepatitis C‐Infected Patients,” Hepatology 64 (2016): 405–414, https://doi.org/10.1002/hep.28625.
J. Wilton, S. Wong, A. Yu, et al., “Real‐World Effectiveness of Sofosbuvir/Velpatasvir for Treatment of Chronic Hepatitis C in British Columbia, Canada: A Population‐Based Cohort Study,” Open Forum Infectious Diseases 7, no. 3 (2020): ofaa055, https://doi.org/10.1093/ofid/ofaa055.
H. Bradley, E. W. Hall, E. M. Rosenthal, P. S. Sullivan, A. B. Ryerson, and E. S. Rosenberg, “Hepatitis C Virus Prevalence in 50 U.S. States and D.C. by Sex, Birth Cohort, and Race: 2013–2016,” Hepatology Communications 4 (2020): 355–370, https://doi.org/10.1002/hep4.1457.
R. Jürgens, M. Nowak, and M. Day, “HIV and Incarceration: Prisons and Detention,” Journal of the International AIDS Society 14 (2011): 26, https://doi.org/10.1186/1758‐2652‐14‐26.
Congressional Research Service, “Offender Reentry: Correctional Statistics, Reintegration Into the Community, and Recidivism.” (2015), Sgp.fas.org/crs/misc/RL34287.pdf.
A. Godin, N. Kronfli, J. Cox, M. Alary, and M. Maheu‐Giroux, “The Role of Prison‐Based Interventions for Hepatitis C Virus (HCV) Micro‐Elimination Among People Who Inject Drugs in Montréal, Canada,” International Journal of Drug Policy 88 (2021): 102738, https://doi.org/10.1016/j.drugpo.2020.102738.
Centers for Disease Control and Prevention, “Viral Hepatitis Surveillance Report – United States, 2021.” (2023), https://www.cdc.gov/hepatitis/statistics/2021surveillance/index.htm.
J. Chhatwal, A. Aaron, H. Zhong, et al., Projected Health Benefits and Health Care Savings From the United States National Hepatitis C Elimination Initiative (Cambridge, MA: National Bureau of Economic Research, 2023), https://www.nber.org/papers/w31139.
X. Zhang, D. Lin, H. Pforsich, and V. W. Lin, “Physician Workforce in The United States of America: Forecasting Nationwide Shortages,” Human Resources for Health 18, no. 1 (2020): 8, https://doi.org/10.1186/s12960‐020‐0448‐3.
J. Chan, M. Akiyama, and E. Julian, “Treating Hepatitis C Infection in Jails as an Offset to Declines in Treatment Activity in the Community, New York City, NY, 2014–2020,” AJPM Focus 3, no. 2 (2024): 100185.